NorthWest Biotherapeutics Inc (NWBO): Unlikely as they are not pivotalp3 trial...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Re: SkyLimit2022 post# 545485

Wednesday, 12/07/2022 6:16:03 PM

Wednesday, December 07, 2022 6:16:03 PM

Unlikely as they are not pivotalp3 trials . The keytruda is p1

THEY HATE ME CAUSE THEY AINT ME

NAILED IT ON EVERY STOCK

Keep Last Read

Next 10 Prev Next

Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM

InvestorsHub NewsWire

Only $200 per official company press release!